In patients with AF, we suggest prescription of oral anticoagulants as a result of an individualized clinical assessment taking into account overall AHRE burden (in the range of hours rather than minutes) and speci cally, the presence of AHRE > 24 h, individual stroke risk (using CHA2DS2-VASc), predicted risk/bene t of oral anticoagulation and informed patient preferences (Ungraded consensus- based statement). Remark: In patients with CIED-detected AHRE, continued patient follow-up is recommended, preferentially combining clinical follow-up with remote monitoring of the CIED or else more frequent device interrogation than standard for CIED follow- up, to detect the development of clinical AF (symptomatic or asymptomatic), to monitor the evolution of AHRE or AF burden and speci cally the transition to AHRE lasting more than 24 h, onset or worsening of heart failure, or any clinical change that might suggest a change in clinical pro le or clinical conditions. Detection of AHRE Patient with a CIED, no previous AF and detection of AHRE ( 5-6 min and Clinical evaluation of device data and evaluation of patient cardiac status and profile Analysis of device electrograms (AF/atrial tachyarrhythmias confirmed? Artifacts excluded?) Consideration for ECG recordings (Holter, patient-operated devices) in specific cases (eg, unavailable electrograms or unclear diagnosis at device electrograms analysis) Clinical risk stratification for stroke (CHA2DS2VASc-score)? 